|
Dr. Spellman is senior vice president of pharmaceutical development at Dynogen. Dr. Spellman has over 20 years of drug development experience with responsibility in areas of analytical development, preclinical development, quality assurance, quality control, and process development for a number of biotechnology companies. Prior to joining Dynogen, he was vice president of quality and then of process development at Millennium Pharmaceuticals. He also served as vice president of preclinical development at Coulter Pharmaceuticals. He was employed for nearly fourteen years at Genentech, Inc., where he led groups in analytical development and product characterization and then served as director of pharmacokinetics and metabolism. During his career in the biotechnology industry, Dr. Spellman has contributed to seven successful licensure applications, and numerous investigational new drug applications. Dr. Spellman received a bachelor’s degree in natural science from Assumption College and a Ph.D. degree in biochemistry from Michigan State University. He did postdoctoral research in the Department of Organic Chemistry at Stockholm University in Sweden. | 